ABBV
Price
$212.53
Change
-$0.47 (-0.22%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
375.5B
48 days until earnings call
AMGN
Price
$283.64
Change
+$3.54 (+1.26%)
Updated
Sep 5 closing price
Capitalization
150.8B
53 days until earnings call
Interact to see
Advertisement

ABBV vs AMGN

Header iconABBV vs AMGN Comparison
Open Charts ABBV vs AMGNBanner chart's image
ABBVIE
Price$212.53
Change-$0.47 (-0.22%)
Volume$19.58K
Capitalization375.5B
Amgen
Price$283.64
Change+$3.54 (+1.26%)
Volume$2.3M
Capitalization150.8B
ABBV vs AMGN Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. AMGN commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a StrongBuy and AMGN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ABBV: $212.56 vs. AMGN: $283.64)
Brand notoriety: ABBV and AMGN are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 91% vs. AMGN: 120%
Market capitalization -- ABBV: $375.5B vs. AMGN: $150.8B
ABBV [@Pharmaceuticals: Major] is valued at $375.5B. AMGN’s [@Pharmaceuticals: Major] market capitalization is $150.8B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $651.91B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $90.72B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 4 FA rating(s) are green whileAMGN’s FA Score has 2 green FA rating(s).

  • ABBV’s FA Score: 4 green, 1 red.
  • AMGN’s FA Score: 2 green, 3 red.
According to our system of comparison, ABBV is a better buy in the long-term than AMGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 4 TA indicator(s) are bullish while AMGN’s TA Score has 4 bullish TA indicator(s).

  • ABBV’s TA Score: 4 bullish, 4 bearish.
  • AMGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than AMGN.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а +1.03% price change this week, while AMGN (@Pharmaceuticals: Major) price change was -1.41% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.16%. For the same industry, the average monthly price growth was +3.97%, and the average quarterly price growth was +10.41%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

AMGN is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.16% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($375B) has a higher market cap than AMGN($151B). ABBV has higher P/E ratio than AMGN: ABBV (101.22) vs AMGN (22.90). ABBV YTD gains are higher at: 22.914 vs. AMGN (12.147). AMGN has higher annual earnings (EBITDA): 15.9B vs. ABBV (14.2B). ABBV has more cash in the bank: 6.47B vs. AMGN (923M). AMGN has less debt than ABBV: AMGN (57.4B) vs ABBV (70.5B). ABBV has higher revenues than AMGN: ABBV (58.3B) vs AMGN (34.9B).
ABBVAMGNABBV / AMGN
Capitalization375B151B248%
EBITDA14.2B15.9B89%
Gain YTD22.91412.147189%
P/E Ratio101.2222.90442%
Revenue58.3B34.9B167%
Total Cash6.47B923M701%
Total Debt70.5B57.4B123%
FUNDAMENTALS RATINGS
ABBV vs AMGN: Fundamental Ratings
ABBV
AMGN
OUTLOOK RATING
1..100
2057
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
14
Undervalued
PROFIT vs RISK RATING
1..100
944
SMR RATING
1..100
1313
PRICE GROWTH RATING
1..100
3062
P/E GROWTH RATING
1..100
1597
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AMGN's Valuation (14) in the Biotechnology industry is significantly better than the same rating for ABBV (88) in the Pharmaceuticals Major industry. This means that AMGN’s stock grew significantly faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (9) in the Pharmaceuticals Major industry is somewhat better than the same rating for AMGN (44) in the Biotechnology industry. This means that ABBV’s stock grew somewhat faster than AMGN’s over the last 12 months.

ABBV's SMR Rating (13) in the Pharmaceuticals Major industry is in the same range as AMGN (13) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.

ABBV's Price Growth Rating (30) in the Pharmaceuticals Major industry is in the same range as AMGN (62) in the Biotechnology industry. This means that ABBV’s stock grew similarly to AMGN’s over the last 12 months.

ABBV's P/E Growth Rating (15) in the Pharmaceuticals Major industry is significantly better than the same rating for AMGN (97) in the Biotechnology industry. This means that ABBV’s stock grew significantly faster than AMGN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVAMGN
RSI
ODDS (%)
Bearish Trend 2 days ago
29%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
43%
Bullish Trend 2 days ago
54%
Momentum
ODDS (%)
Bullish Trend 3 days ago
62%
Bearish Trend 2 days ago
51%
MACD
ODDS (%)
Bullish Trend 3 days ago
58%
Bearish Trend 2 days ago
50%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
59%
Bearish Trend 2 days ago
56%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
61%
Bearish Trend 2 days ago
49%
Advances
ODDS (%)
Bullish Trend 4 days ago
57%
Bullish Trend 17 days ago
56%
Declines
ODDS (%)
Bearish Trend 9 days ago
44%
Bearish Trend 2 days ago
53%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
45%
Bullish Trend 2 days ago
63%
Aroon
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AMGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
KSTR17.470.76
+4.55%
KraneShares SSE STAR Market 50 ETF
TMFM26.110.22
+0.86%
Motley Fool Mid-Cap Growth ETF
IQLT43.420.28
+0.65%
iShares MSCI Intl Quality Factor ETF
LONZ50.850.03
+0.07%
PIMCO Sr Ln Actv ETF
AUGU28.22-0.06
-0.22%
AllianzIM U.S. Equity Buffer15 UncAugETF